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Abstract In the West, the incidence of esophageal ade-
nocarcinoma, which is a long-term complication of damage
by gastroesophageal reflux, has been rising over recent
decades. Two main factors are likely to account for this
increase. The first is the rising incidence of central obesity
which promotes gastroesophageal reflux. The second is the
falling incidence of H. pylori infection and associated
atrophic gastritis which reduces the acidity and peptic
activity of gastric juice, the main factors damaging to the
esophageal mucosa. The rise in esophageal adenocarci-
noma has been mirrored by a fall in gastric cancer con-
sistent with H. pylori atrophic gastritis protecting from the
former and predisposing to the latter. The incidence of
gastric cancer in Japan is still above the level at which a
rise in esophageal adenocarcinoma became apparent in the
West. Esophageal adenocarcinoma is likely to rise in Japan
also as the incidence of gastric cancer falls but the degree
of rise will depend on a variety of other environmental and
genetic factors.
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Introduction
There has been a marked and steady increase in the inci-
dence of oesophageal adenocarcinoma in the Western
world [1, 2]. This has been apparent, particularly in
Western Europe and North America. The average annual
increase in the cancer has ranged from 3.5% in Scotland to
8.1% in Hawaii. In the Western world, there has also been
a simultaneous fall in the incidence of gastric adenocarci-
noma, though that decline started many decades before the
rise in the incidence of oesophageal adenocarcinoma
became apparent [2]. Some of the recorded increase in
incidence of oesophageal adenocarcinoma might be due to
cancers at the gastro-oesophagael junction being more
frequently classified as oesophageal rather than gastric
cancers in recent years but this would only account for a
small component of the marked changes seen.
To explore the possible reasons for the recent increase in
incidence of oesophageal adenocarcinoma, it is necessary
to understand the aetiology of this cancer. Oesophageal
adenocarcinoma is believed to be a long-term complication
of chronic damage to the oesophageal mucosa by reflux of
gastric juice [3]. Unlike gastric columnar mucosa, the
oesophageal squamous mucosa is unable to withstand the
damaging effects of the acid and pepsin in gastric juice
along with bile, which may also be present in the stomach.
The gastric juice causes erosion and ulceration of the
squamous mucosa and with ongoing damage, the squamous
epithelium undergoes metaplasia to columnar type epithe-
lium which is much less susceptible to the chemical insult
of gastric juice. This metaplastic epithelium may resemble
gastric cardia epithelium or that of the small and large
bowel when it’s referred to as intestinal metaplasia. This
metaplastic epithelium is referred to as Barrett’s oesopha-
gus and has a propensity to develop dysplasia and progress
to adenocarcinoma.
Accurate information regarding changes in incidence of
gastro-oesophageal reflux disease is more difficult to obtain
than that on esophageal cancer. The information available,
however, does suggest that in the Western world, reflux
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disease has increased substantially over the last few dec-
ades and at a rate similar to that of oesophageal adeno-
carcinoma [4]. It seems likely, therefore, that the increase
in incidence of oesophageal adenocarcinoma can be largely
or entirely explained by a rising incidence in gastro-oe-
sophageal reflux disease. We must now explore the possi-
ble explanations for the rising incidence of reflux disease in
the Western world over recent decades.
Gastro-oesophageal reflux occurs when there is failure
of the lower oesophageal sphincter mechanism to prevent
gastric juice refluxing up into the oesophagus. One
important factor in promoting such reflux is central obesity.
There is a strong positive association between waist cir-
cumference or BMI and reflux symptoms [5, 6]. One
important mechanism by which central obesity promotes
gastro-oesophageal reflux is by increasing intra-abdominal
pressure and the gastro-oesophageal pressure gradient and
this causes an increase in the rate of flow of gastric juice
into the oesophagus whenever the lower oesophageal
sphincter is open [7]. This increased intra-abdominal
pressure also impairs oesophageal clearance of gastric
refluxate [7]. There has been a marked increase in inci-
dence of central obesity in the Western world over the past
few decades and this is likely to be one factor contributing
to the increase in reflux disease, and thus that of oeso-
phageal adenocarcinoma [4]. Obesity is also linked to an
increasing incidence of other cancers and it is possible that
obesity is promoting oesophageal carcinoma by humoral
mechanisms in addition to its mechanical effects [8].
The degree to which the gastro-esophageal reflux will
damage the oesophageal mucosa will depend upon the
nature of the refluxate and, in particular, its concentration
of acid, pepsin and bile. Helicobacter pylori infection can
result in atrophic gastritis with a loss in parietal and chief
cell numbers, and thus a reduction in the concentration of
acid and pepsin secreted by the stomach. We have been
interested in the possible role of H. pylori infection in the
rising incidence of gastro-oesophageal reflux disease and
oesophageal adenocarcinoma.
There is a strong negative association between H. pylori
infection and gastroesophageal reflux disease documented
in the Western world [9]. In addition, there is also a strong
negative association between Helicobacter pylori infection
and oesophageal adenocarcinoma with the incidence of the
cancer in H. pylori positive subjects being only 30–50% of
that in H. pylori negatives [10]. The prevalence of H. pylori
infection in the Western world has been falling over recent
decades and the rise in oesophageal adenocarcinoma might
therefore be explained by the loss of a protective effect of
the infection against reflux disease [11].
The most plausible mechanism by which H. pylori
infection might prevent oesophageal damage by refluxing
gastric juice is by reducing the concentrations of acid and
pepsin in the juice as a consequence of the infection
inducing atrophic gastritis. In order for the infection to
produce a significant protective effect, it would need to
produce this effect in the majority of H. pylori infected
subjects. Many studies have reported the effects of H.
pylori infection on the gastric mucosa and its secretory
function but most of these studies have been performed on
patients with specific diseases arising from the infection,
such as duodenal or gastric ulcers or gastric cancer. There
are very few studies which have examined the effect of the
infection on gastric secretory function in the general
population.
We have recently investigated the association between
H. pylori infection and gastric mucosal function in repre-
sentative volunteers of our general populations in Scotland,
which is a country which has experienced the changes in
the incidence of oesophageal and gastric adenocarcinoma
similar to the rest of the Western world. The studies were
conducted in 28 H. pylori positive and 31 H. pylori nega-
tive subjects matched for age, sex and BMI [2]. The mean
age of both groups was 55 years. We found that the density
of parietal and chief cells from our infected volunteers was
only approximately 50% of that in H. pylori negatives and
that the reduction in cell density was most marked at the
junction between the body and antral mucosa and also
between the body and cardia mucosa proximally. We also
studied intragastric acidity using high resolution pH-metry
with 12 pH sensors cited throughout the stomach and this
was undertaken both fasted and following a meal. In the H.
pylori positive subjects, intragastric acidity was substan-
tially less in all regions of the stomach compared to the H.
pylori negatives under fasting conditions. Intragastric
acidity was also substantially less in the H. pylori positives
after the meal and this was most marked in the proximal
stomach close to the gastroesophageal junction (Fig. 1).
Under fasting conditions, the median pH in the H. pylori
negative subjects close to the gastroesophageal junction
was 2, compared to 6 in the H. pylori positives. Likewise,
after the meal, the median intragastric pH close to the
gastroesophageal junction in the H. pylori negatives
remained at 2, whereas in the H. pylori positives it
remained above 4. These studies demonstrate that the
gastric juice of H. pylori infected subjects will be much
less damaging to the oesophageal mucosa than that of
uninfected subjects.
The above studies were performed in subjects with a
mean age of 55 years and the gastric juice in younger
subjects with H. pylori infection might have higher con-
centrations of acid and pepsin. It should, however, be
remembered that incompetence of the lower oesophageal
sphincter tends to occur with advancing years and, there-
fore, it will be the properties of the gastric juice at an age
when reflux occurs that will be important.
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The above population studies, therefore, provide strong
evidence of a protective effect of H. pylori infection
against the damaging effects of refluxing gastric juice and
are consistent with the falling incidence of H. pylori
infection and loss of this protective effect contributing to
the rising incidence of reflux disease and its complication
of oesophageal adenocarcinoma.
If the rising incidence of oesophageal adenocarcinoma is
indeed due to a loss of the protective effects of H. pylori
atrophic gastritis, then there should be a negative associa-
tion between incidences of oesophageal adenocarcinoma
and gastric adenocarcinoma for which H. pylori atrophic
gastritis is the major risk factor. If H. pylori atrophic gas-
tritis is both causing gastric cancer and protecting from
oesophageal adenocarcinoma then we should see a nega-
tive association between the incidences of these two can-
cers. We have, therefore, recently investigated the
association between oesophageal adenocarcinoma and
gastric adenocarcinoma in collaboration with Forman et al.
at the International Agency for Research into Cancer at
Lyon [2].
There is a large range in incidence of both oesophageal
adenocarcinoma and gastric adenocarcinoma across dif-
ferent countries of the world. We have observed a strong
negative correlation between the current incidence of
gastric adenocarcinoma and oesophageal adenocarcinoma
across these countries [2]. In countries with an incidence of
gastric adenocarcinoma of more than 10, oesophageal
adenocarcinoma was consistently low (Fig. 2). This is
consistent with H. pylori atrophic gastritis predisposing to
gastric cancer and protecting from esophageal
adenocarcinoma. In countries with an incidence of gastric
adenocarcinoma of less than 10, oesophageal adenocarci-
noma was high but not always high. This is consistent with
the absence of H. pylori induced atrophic gastritis being a
permissive factor for esophageal adenocarcinoma but other
promoting factors in particular gastroesophageal also being
required.
We have also investigated the relationship between
changing incidences of oesophageal adenocarcinoma and
gastric adenocarcinoma over the past 20–50 years using
populations from 38 different countries [2]. 66% of these
countries showed a significant increase in gastric adeno-
carcinoma and 95% of the countries showed a significant
decrease in gastric adenocarcinoma. In 28 of these 38
Fig. 1 Median pH for 0–30 min
period after meal relative to
LES and SCJ in H. pylori
positive (HP?) and negative
(HP-) subjects. Reproduced by
permission from Mitchell et al.
[12]
Fig. 2 Correlations between incidence rates (WASR) of esophageal
adenocarcinoma and gastric cancer in men. Each dot represents a
dataset from an individual country. Reproduced by permission from
Derakhshan et al. [2]
J Gastroenterol (2019) 54:669–673 671
123
countries, there was a significant negative correlation
between the changing incidence of the two cancers and no
country showed a positive correlation.
These epidemiological studies therefore show a strong
negative correlation between both current prevalences and
changing incidences in oesophageal adenocarcinoma and
gastric adenocarcinoma throughout the world [2]. These
findings are consistent with H. pylori atrophic gastritis both
predisposing to gastric adenocarcinoma and protecting
from oesophageal adenocarcinoma and the falling inci-
dence of H. pylori atrophic gastritis causing a falling
incidence in gastric adenocarcinoma and a simultaneous
rising incidence in gastric adenocarcinoma. These epi-
demiological studies combined with the physiological
effects of H. pylori infection on gastric mucosal structure
and function provide compelling evidence that the falling
incidence of H. pylori infection is likely to be an important
contributory factor to the rising incidence of oesophageal
adenocarcinoma. The falling incidence of H. pylori infec-
tion along with the rise in the prevalence of central obesity
are, therefore, two key factors explaining the recent
increases in oesophageal adenocarcinoma observed in parts
of the Western world.
The final and important question to be addressed is
whether there will be a significant and substantial increase
in oesophageal adenocarcinoma in Japan and other Eastern
countries similar to that which has been seen in Western
countries. As discussed above, the rise in oesophageal
adenocarcinoma in Western countries and accompanying
fall in gastric adenocarcinoma is thought to reflect the loss
of protective effect of H. pylori atrophic gastritis. Japan
currently still has a relatively high incidence of gastric
adenocarcinoma and a very low incidence of oesophageal
adenocarcinoma similar to the pattern seen in Western
countries several decades ago. The incidence of gastric
adenocarcinoma, however, is falling in Japan and will that
herald an increase in oesophageal adenocarcinoma? Our
epidemiological studies of the incidences of gastric and
oesophageal adenocarcinoma indicated that a significant
rise in oesophageal adenocarcinoma only appeared when
the incidence of gastric adenocarcinoma fell below 10 [2].
The incidence of gastric adenocarcinoma in Japan remains
above 10 and thus still above the level at which a rise in the
incidence of oesophageal adenocarcinoma became appar-
ent in the West. It is, therefore, too early to say whether the
falling incidence of gastric adenocarcinoma will be
accompanied by a significant rise in oesophageal adeno-
carcinoma in Japan.
Our epidemiological studies also indicated that a fall in
gastric adenocarcinoma was not necessarily accompanied
by a rise in oesophageal adenocarcinoma [2]. We interpret
this as being consistent with a loss of atrophic gastritis and
rise in acidity and peptic activity of gastric juice not
necessarily being associated with a rise in oesophageal
adenocarcinoma. This makes physiological sense as oeso-
phageal damage depends not only on the acidity and peptic
activity of the gastric juice but also upon failure of the
lower oesophageal sphincter due to other factors such as
central obesity. The extent to which the incidence of reflux
disease and oesophageal adenocarcinoma are likely to rise
in future decades in Japan following the disappearance of
the protective effect of H. pylori infection and atrophic
gastritis will depend upon the presence of other co-factors
contributing to the pathogenesis of reflux disease such as
central obesity. It should also be recognised that there are
likely to be many other genetic and environmental factors
other than H. pylori infection and central obesity con-
tributing to the aetiology of reflux disease and its compli-
cation of oesophageal adenocarcinoma and the incidence of
these in Japan will also determine the degree of increase in
incidence of oesophageal adenocarcinoma in future
decades.
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